Uganda Pharmaceuticals and Healthcare Report Q4 2017
We believe that the private sector will remain dominant over our forecast period to 2026, as Uganda's reliance on aid funding and the basic nature of the country's public health spending suggests a weak outlook for public healthcare sector provision. Strong private consumption growth will drive medicine spending, with opportunities being presented for multinationals selling high-value patented drugs.
Headline Expenditure Projections
Pharmaceuticals: UGX1,374bn (USD394mn) in 2016 to UGX1,497bn (USD416mn) in 2017; +9.0% growth in local currency terms and 5.5% in US dollar terms. Forecast in US dollar terms increased from last quarter.
Healthcare: UGX5,858bn (USD1.68bn) in 2016 to UGX6,259bn (USD1.74bn) in 2017; +6.8% growth in local currency terms and 3.5% in US dollar terms. Forecast increased from last quarter.
In August 2017, the National Drug Authority warned about counterfeit drugs, Sutent and Avastin, being sold in Uganda after it had obtained samples of counterfeit drugs and handed the information to the prosecutor (Daily Monitor).